EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): UPDATED SAFETY ANALYSIS

被引：0
|
作者：
Nicolini, F. [1 ]
Alimena, G. [2 ]
Shen, Z. [3 ]
Al-Ali, H. -K [4 ]
Turkina, A. [5 ]
Smith, G. [6 ]
Pasquini, R. [7 ]
Jootar, S. [8 ]
Hsu, Y. [9 ]
Veronese, M. L. [9 ]
Powell, B. [10 ]
机构：
[1] Hop Edouard Herriot, Lyon, France
[2] Univ Roma La Sapienza, Rome, Italy
[3] Shanghai Jiao Tong Univ, Rui Jin Hosp, Sch Med, Shanghai 200030, Peoples R China
[4] Univ Leipzig, Med Klin & Poliklin 2, Leipzig, Germany
[5] Hematol Sci Ctr, Moscow, Russia
[6] Leeds Teaching Hosp, Leeds, W Yorkshire, England
[7] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil
[8] Mahidol Univ, Salaya, Thailand
[9] Nova Pharmaceut Corp, E Hanover, NJ USA
[10] Wake Forest Univ, Baptist Med Ctr, Ctr Comprehens Canc, Winston Salem, NC 27109 USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O134
引用
收藏
页码：53 / 53
页数：1
相关论文
共 50 条
  • [1] EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR-INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): FINAL SAFETY ANALYSIS OF 117 CHINESE CML PATIENTS
    Shen, Z.
    Huang, X.
    Meng, F.
    Wang, J.
    Liu, T.
    Hu, J.
    Wang, J.
    Zhao, Y.
    Woodman, R.
    Zou, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 348 - 349
  • [2] FINAL SAFETY ANALYSIS OF 1,793 CML PATIENTS FROM ENACT (EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA
    Nicolini, F. E.
    Alimena, G.
    Al-Ali, H. K.
    Turkina, A. T.
    Shen, Z.
    Jootar, S.
    Smith, G.
    De Souza, C.
    Wang, J.
    Berton, M.
    Szczudlo, T.
    Rizzieri, D. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 255 - 256
  • [3] Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study
    le Coutre, Philipp D.
    Turkina, Anna
    Kim, Dong-Wook
    Ceglarek, Bernadeta
    Alimena, Giuliana
    Al-Ali, Haifa Kathrin
    Shen, Zhixiang
    Jootar, Saengsuree
    Smith, Graeme
    De Souza, Carmino Antonio
    Dorlhiac-Llacer, Pedro Enrique
    Rizzieri, David A.
    Szczudlo, Tomasz
    Berton, Myriam
    Wang, Jim
    Wang, Si-Tien
    Nicolini, Franck Emmanuel
    BLOOD, 2009, 114 (22) : 1272 - 1273
  • [4] Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.
    le Coutre, Philipp D.
    Ceglarek, Bernadeta
    Turkina, Anna
    Kim, Dong-Wook
    Alimena, Giuliana
    Al-Ali, Haifa Kathrin
    Shen, Zhixiang
    Jootar, Saengsuree
    Smith, Graeme
    De Souza, Carmino Antonio
    Rizzieri, David A.
    Szczudlo, Tomasz
    Berton, Myriam
    Wang, Jim
    Dial, Ellison
    Nicolini, Franck Emmanuel
    BLOOD, 2009, 114 (22) : 457 - 458
  • [5] EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS (PTS) WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): SUBGROUP ANALYSIS OF PATIENTS WHO FAILED PRIOR DASATINIB THERAPY
    Nicolini, F. E.
    Alimena, G.
    Al-Ali, H. K.
    Turkina, A. T.
    Shen, Z.
    Jootar, S.
    Smith, G.
    Conchon, M.
    Wang, J.
    Berton, M.
    Szczudlo, T.
    Rizzieri, D. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 257 - 257
  • [6] ENACT (Expanding Nilotinib Access in Clinical Trials) study in adult patients (pts) with Imatinib-resistant or - intolerant Chronic Myeloid Leukemia (CML): Subgroup analysis of Pts from Germany, Austria and Switzerland (DACH)
    Al-Ali, H. K.
    le Coutre, P.
    Duyster, J.
    Linkesch, W.
    Wolf, D.
    Schanz, U.
    Baerlocher, G. M.
    Wackwitz, B.
    Heim, D.
    ONKOLOGIE, 2011, 34 : 267 - 267
  • [7] Expanding nilotinib access in clinical trials (ENACT) study in adult patients (Pts) with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in blast crisis (BC), accelerated phase (AP), or chronic phase (CP): Preliminary safety analysis
    Nicolini, Franck
    Alimena, Giuliana
    Al-Ali, Haifa-Kathrin
    Zaritskey, Andrey
    Shen, Zhixiang
    Jootar, Saengsuree
    Smith, Graeme
    Hsu, Yanzhi
    Veronese, Maria Luisa
    Rizzieri, David A.
    BLOOD, 2007, 110 (11) : 870A - 870A
  • [8] Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis
    Nicolini, Franck E.
    Masszi, Tamas
    Shen, Zhixiang
    Gallagher, Neil J.
    Jootar, Saengsuree
    Powell, Bayard L.
    Dorlhiac-Llacer, Pedro Enrique
    Zheng, Ming
    Szczudlo, Tomasz
    Turkina, Anna
    LEUKEMIA & LYMPHOMA, 2012, 53 (05) : 907 - 914
  • [9] NILOTINIB SAFETY AND RESPONSES ANALYSIS IN RUSSIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) FROM ENACT(EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS) STUDY
    Turkina, A.
    Khoroshko, N.
    Bakirov, A.
    Korobkin, A.
    Pospelova, T.
    Rossiev, V.
    Shatokhin, Y.
    Silin, A.
    Zaritsky, A.
    Kravchenko, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 534 - 534
  • [10] Expanding Nilotinib Access in Clinical Trials (ENACT) An Open-Label, Multicenter Study of Oral Nilotinib in Adult Patients With Imatinib-Resistant or Imatinib-Intolerant Philadelphi Chromosome-Positive Chronic Myeloid Leukemia in the Chronic Phase
    Nicolini, Franck E.
    Turkina, Anna
    Shen, Zhi-Xiang
    Gallagher, Neil
    Jootar, Saengsuree
    Powell, Bayard L.
    De Souza, Carmino
    Zheng, Ming
    Szczudlo, Tomasz
    le Coutre, Philipp
    CANCER, 2012, 118 (01) : 118 - 126
12345